Table of Contents

company-logo

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Ultragenyx Pharmaceutical Dividend Announcement

• Ultragenyx Pharmaceutical does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Ultragenyx Pharmaceutical dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Ultragenyx Pharmaceutical Dividend History

Ultragenyx Pharmaceutical Dividend Yield

Ultragenyx Pharmaceutical current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Ultragenyx Pharmaceutical stock? Use our calculator to estimate your expected dividend yield:

Ultragenyx Pharmaceutical Financial Ratios

P/E ratio-8.43
PEG ratio0.42
P/B ratio13.58
ROE-187.12%
Payout ratio0.00%
Current ratio2.81
Quick ratio2.65
Cash Ratio0.53

Ultragenyx Pharmaceutical Dividend FAQ

Does Ultragenyx Pharmaceutical stock pay dividends?
Ultragenyx Pharmaceutical does not currently pay dividends to its shareholders.
Has Ultragenyx Pharmaceutical ever paid a dividend?
No, Ultragenyx Pharmaceutical has no a history of paying dividends to its shareholders. Ultragenyx Pharmaceutical is not known for its dividend payments.
Why doesn't Ultragenyx Pharmaceutical pay dividends?
There are several potential reasons why Ultragenyx Pharmaceutical would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Ultragenyx Pharmaceutical ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Ultragenyx Pharmaceutical has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Ultragenyx Pharmaceutical a dividend aristocrat?
Ultragenyx Pharmaceutical is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Ultragenyx Pharmaceutical a dividend king?
Ultragenyx Pharmaceutical is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Ultragenyx Pharmaceutical a dividend stock?
No, Ultragenyx Pharmaceutical is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Ultragenyx Pharmaceutical stocks?
To buy Ultragenyx Pharmaceutical you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Ultragenyx Pharmaceutical stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.